The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Ghia 100% correct TR1 from Lansdowne to come and I am thinking our US friends want a bit more so would not be surprised to see today’s arm of their investment take up 5% at least. Whether that comes before news let’s see .....
Complete BS there is more than one person in the SNG team and to think they have not contributed throughout the journey is crazy. The poster should be held accountable for that and dealt with accordingly. The depths some people will go to.
Hands up who sold?? TR1 next week taking them over 5% order filled this morning the question is what is there target holding?!
Why are people expecting peer reviews shortly? The company has not released the full results yet! How can anyone peer review on headline data? And it really bears little significance the only significant element is regulatory approval. Get that and we are in business!
Let’s not get ahead of ourselves the article makes no reference to the upcoming trial being inhaled infer B and also references trials involving infer B in Hong Kong which were not inhaled. No evidence to suggest it is us, the article though is another positive endorsement.
Why is everyone pinning such importance to peer reviews? The fundamental importance here is approval. Regulators will have our applications and have worked with us all the way through from trial approval to protocol and expediating the trial in the hospitals. None of that is dependent on peer review and look at the calibre of the founders of Synairgen do you think they would mess up? This is more about the authorities choice of speed in relation to approvals that’s what we are all guessing. RM has indicated we won’t be waiting past mid August for our answer.
Are you sure about that? So if we get FDA approval we need to wait until 4:30? I don’t think that is correct
I aka bit confused by this DR Goodacre comments, I found the registration and protocol for this trial months ago very easily. How can someone of his calibre be so uneducated? Am I missing something? The registration clearly had cover for 400 patients with a protocol laid out for all to see, expecting full publication of results this week and hope that silenced the critics.
They are not going to be waiting until 2021 to get this approved. Who is going to hold it up in the midst of a global pandemic that no one has seen before? MF2017 strongly disagree with you, let’s see who turns out right. COPD data unblinded to help with immediate approval.
100% with a mentality that I can lose it all which got me through the tough months, topped up numerous times with money saved from home working due to Covid. Didn’t get the timing right on half of them!!I view this share as the opportunity, if the moons align then it’s big money which will sit under lock and key until I want to release it rather than need to release it. Impressed with the way they have seized the opportunity and the placing impressed me, funds well used and thought out. Talks have been ongoing in the background for months and they know data is key, they work with good companies who know their area of expertise. Yes they are more science orientated than business orientated but they are clever and their contacts in the field of expertise will ensure they command the respect needed to get the approvals and the partnership required. Orders already being placed??
And they have worked with Transcript for over 12 years, Transcript Specialise in supporting companies with getting drugs to market and passing regulatory tests. SNG is small specialising in Research they need to bring in additional support, licence deal IMO RM has shown he will move fast to deliver they know now is the time and they are going for it, he always stressed about the data being key so I fully expect it to deliver approval.
Sparkle they use a company to help with the trials and I believe they appointed advisors to support with negotiations for partnering discussions. They set aside 3 million for this purpose. Very well thought out and planned operations, they won’t be doing a phase 3 alone if at all.
John I think you are right, revealing the COPD data has been done for a purpose that purpose is to further demonstrate safety and effectiveness of SNG001. RM will be pushing to skip phase 3 and who knows maybe a condition of approval is the COPD data, they have been in regular contact with the regulators, they are not amateurs here. Who wants to be responsible for holding up a treatment for the worst pandemic in our lifetime by insisting on phase 3 trials, they won’t it will get approved.
Could be some II selling that pulled us down and now the brakes have come off, more likely news tomorrow.
Filled an order or it’s 7am tomorrow morning for an update
Someone’s buying , TR1 to come. Big thank you to all the PIs who sold out deep pockets moving in.
Positions being taken, money moving from the trader to the investor, the next leg will come. Double your money start of September?
Hey Johnnys back called this one! What an expert
RE: Buys08 Jun 2020 19:54
The one shining light in the on-going decimation of the share price is that, when the day of reckoning comes, the fall over the cliff won't be that bad for most because they will be half way down already.
Once approved for commercial use this will have huge value, winter season coming up and second wave of Covid likely to strike. They won’t be able to manage demand so will need to partner up and this has always been the plan as they are a small research company not a drug producer. There are some really exciting times ahead, I don’t doubt the SP will drift and consolidate but all the sells are being taken and positions being built/improved. I can’t see authorities sitting on this it’s safe and works and needs to get to those who need it. Riding it out until the end for the full value once in a lifetime sit tight and enjoy what the summer brings.
He is a long term holder been here longer than April, and has just sold off a bit nothing more.